180 related articles for article (PubMed ID: 27149910)
1. Significant impacts of CYP3A4*1G and CYP3A5*3 genetic polymorphisms on the pharmacokinetics of diltiazem and its main metabolites in Chinese adult kidney transplant patients.
Zhou LY; Zuo XC; Chen K; Wang JL; Chen QJ; Zhou YN; Yuan H; Ma Y; Zhu LJ; Peng YX; Ming YZ
J Clin Pharm Ther; 2016 Jun; 41(3):341-7. PubMed ID: 27149910
[TBL] [Abstract][Full Text] [Related]
2. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.
Zuo XC; Ng CM; Barrett JS; Luo AJ; Zhang BK; Deng CH; Xi LY; Cheng K; Ming YZ; Yang GP; Pei Q; Zhu LJ; Yuan H; Liao HQ; Ding JJ; Wu D; Zhou YN; Jing NN; Huang ZJ
Pharmacogenet Genomics; 2013 May; 23(5):251-61. PubMed ID: 23459029
[TBL] [Abstract][Full Text] [Related]
3. Effect of genetic polymorphisms of CYP3A5 and MDR1 on cyclosporine concentration during the early stage after renal transplantation in Chinese patients co-treated with diltiazem.
Wang Y; Wang C; Li J; Wang X; Zhu G; Chen X; Bi H; Huang M
Eur J Clin Pharmacol; 2009 Mar; 65(3):239-47. PubMed ID: 18936931
[TBL] [Abstract][Full Text] [Related]
4. Effects of CYP3A5 and CYP2D6 genetic polymorphism on the pharmacokinetics of diltiazem and its metabolites in Chinese subjects.
Zheng T; Su CH; Zhao J; Zhang XJ; Zhang TY; Zhang LR; Kan QC; Zhang SJ
Pharmazie; 2013 Apr; 68(4):257-60. PubMed ID: 23700791
[TBL] [Abstract][Full Text] [Related]
5. Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients.
Miura M; Satoh S; Kagaya H; Saito M; Numakura K; Tsuchiya N; Habuchi T
Pharmacogenomics; 2011 Jul; 12(7):977-84. PubMed ID: 21635144
[TBL] [Abstract][Full Text] [Related]
6. Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation.
Hu YF; Qiu W; Liu ZQ; Zhu LJ; Liu ZQ; Tu JH; Wang D; Li Z; He J; Zhong GP; Zhou G; Zhou HH
Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1093-8. PubMed ID: 17042920
[TBL] [Abstract][Full Text] [Related]
7. Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients.
Qiu XY; Jiao Z; Zhang M; Zhong LJ; Liang HQ; Ma CL; Zhang L; Zhong MK
Eur J Clin Pharmacol; 2008 Nov; 64(11):1069-84. PubMed ID: 18636247
[TBL] [Abstract][Full Text] [Related]
8. Effects of CYP3A4*1G and CYP3A5*3 polymorphisms on pharmacokinetics of tylerdipine hydrochloride in healthy Chinese subjects.
Zhou S; Tao M; Wang Y; Wang L; Xie L; Chen J; Zhao Y; Liu Y; Zhang H; Ou N; Wang G; Shao F; Aa J
Xenobiotica; 2019 Mar; 49(3):375-380. PubMed ID: 29521134
[TBL] [Abstract][Full Text] [Related]
9. Diltiazem on tacrolimus exposure and dose sparing in Chinese pediatric primary nephrotic syndrome: impact of CYP3A4, CYP3A5, ABCB1, and SLCO1B3 polymorphisms.
Wang J; Huang L; Gao P; Hu Y; Ni Y; Zhu Z; Zhang L; Yang J; Zhang H; Fang L
Eur J Clin Pharmacol; 2021 Jan; 77(1):71-77. PubMed ID: 32803289
[TBL] [Abstract][Full Text] [Related]
10. CYP3A4/5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients.
Li DY; Teng RC; Zhu HJ; Fang Y
Int J Clin Pharmacol Ther; 2013 Jun; 51(6):466-74. PubMed ID: 23557867
[TBL] [Abstract][Full Text] [Related]
11. Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients.
Żochowska D; Wyzgał J; Pączek L
Ann Transplant; 2012; 17(3):36-44. PubMed ID: 23018254
[TBL] [Abstract][Full Text] [Related]
12. Association of CYP3A polymorphisms with the pharmacokinetics of cyclosporine A in early post-renal transplant recipients in China.
Meng XG; Guo CX; Feng GQ; Zhao YC; Zhou BT; Han JL; Chen X; Shi Y; Shi HY; Yin JY; Peng XD; Pei Q; Zhang W; Wang G; He M; Liu M; Yang JK; Zhou HH
Acta Pharmacol Sin; 2012 Dec; 33(12):1563-70. PubMed ID: 23085740
[TBL] [Abstract][Full Text] [Related]
13. CYP3A4*1G and CYP3A5*3 genetic polymorphisms alter the antihypertensive efficacy of amlodipine in patients with hypertension following renal transplantation
.
Huang Y; Wen G; Lu Y; Wen J; Ji Y; Xing X; Li Y; Wen J; Yuan H
Int J Clin Pharmacol Ther; 2017 Feb; 55(2):109-118. PubMed ID: 27841150
[TBL] [Abstract][Full Text] [Related]
14. Effect of CYP3A4*1G, CYP3A5*3, POR*28, and ABCB1 C3435T on the pharmacokinetics of nifedipine in healthy Chinese volunteers.
Wang XF; Yan L; Cao HM; Wei LM; Yang WH; Zhang SJ; Zhang LR
Int J Clin Pharmacol Ther; 2015 Sep; 53(9):737-45. PubMed ID: 26104034
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.
Hesselink DA; van Schaik RH; van der Heiden IP; van der Werf M; Gregoor PJ; Lindemans J; Weimar W; van Gelder T
Clin Pharmacol Ther; 2003 Sep; 74(3):245-54. PubMed ID: 12966368
[TBL] [Abstract][Full Text] [Related]
16. Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective.
Li JL; Wang XD; Chen SY; Liu LS; Fu Q; Chen X; Teng LC; Wang CX; Huang M
Pharmacogenomics J; 2011 Aug; 11(4):300-6. PubMed ID: 20514078
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Influence of CYP3A5, CYP3A4, ABCB1, and NR1I2 Polymorphisms on Tacrolimus Concentration in Chinese Renal Transplant Recipients.
Liu F; Ou YM; Yu AR; Xiong L; Xin HW
Genet Test Mol Biomarkers; 2017 Nov; 21(11):663-673. PubMed ID: 28945481
[TBL] [Abstract][Full Text] [Related]
18. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.
Elens L; Bouamar R; Hesselink DA; Haufroid V; van der Heiden IP; van Gelder T; van Schaik RH
Clin Chem; 2011 Nov; 57(11):1574-83. PubMed ID: 21903774
[TBL] [Abstract][Full Text] [Related]
19. CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III).
Yoon SH; Cho JH; Kwon O; Choi JY; Park SH; Kim YL; Yoon YR; Won DI; Kim CD
Transplantation; 2013 Mar; 95(6):828-34. PubMed ID: 23364483
[TBL] [Abstract][Full Text] [Related]
20. Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients.
Elens L; Hesselink DA; Bouamar R; Budde K; de Fijter JW; De Meyer M; Mourad M; Kuypers DR; Haufroid V; van Gelder T; van Schaik RH
Ther Drug Monit; 2014 Feb; 36(1):71-9. PubMed ID: 24061445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
